Biocon receives establishment inspection report from U.S. FDA

Biocon on Monday said it had received an establishment inspection report (EIR) with voluntary action indicated (VAI) status from the U.S. Food and Drug Administration (FDA), for its active pharmaceutical ingredient (API) facility (site 2) located at the SEZ on Bommasandra-Jigani Link Road in Bengaluru, Karnataka. The action was based on a surveillance inspection conducted by the agency between September 23 and 27, the biopharmaceutical company said.